Ligand Pharma Stock Price, News & Analysis
Company Description
Ligand Pharma (OTC Link: LGNDZ) is a publicly traded company.
LGNDZ stock has declined 40.0% over the past year. Shares last traded at $0.0018.
On a trailing twelve-month basis, Ligand Pharma reported revenue of $268.1M with net income of $124.5M and diluted earnings per share of $6.13. The company operates at a net profit margin of 46.4%.
This page provides a comprehensive overview of LGNDZ stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Ligand Pharma (LGNDZ) stock last traded at $0.0018. Over the past 12 months, the stock has lost 40.0%.
Latest News
SEC Filings
Ligand Pharma has filed 5 recent SEC filings, including 4 Form 4, 1 Form 144. The most recent filing was submitted on April 2, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all LGNDZ SEC filings →
Financial Highlights
Ligand Pharma generated $268.1M in revenue over the trailing twelve months, operating income reached $41.0M (15.3% operating margin), and net income was $124.5M, reflecting a 46.4% net profit margin. Diluted earnings per share stood at $6.13. The company generated $49.4M in operating cash flow. With a current ratio of 22.23, the balance sheet reflects a strong liquidity position.
Upcoming Events
Short Interest History
Short interest in Ligand Pharma (LGNDZ) currently stands at 18.8 thousand shares, up 7750.8% from the previous reporting period. Over the past 12 months, short interest has increased by 7750.8%.
Days to Cover History
Days to cover for Ligand Pharma (LGNDZ) currently stands at 1.0 days. This low days-to-cover ratio indicates high liquidity, allowing short sellers to quickly exit positions if needed.